Candesartan Cilexetil

證據等級: L5

預測適應症: 10 個

Candesartan Cilexetil: From Hypertension to Cerebrovascular Disorder

One-Sentence Summary

Candesartan cilexetil is a potent, highly selective angiotensin II type 1 (AT1) receptor antagonist widely used for hypertension and chronic heart failure. The TxGNN model predicts it may be effective for Cerebrovascular Disorder — the highest-evidence prediction in this evidence pack — with 12 clinical trials (including two Phase 3 RCTs) and 20 publications currently supporting this direction. This indication has reached Evidence Level L1 with a "Proceed with Guardrails" recommendation.

Editorial Note: The TxGNN model's highest-scored predictions (malignant renovascular hypertension, malignant hypertensive renal disease) carry scores of ~99.68% but have zero supporting clinical trials or literature (L5 / Hold). This report prioritises Cerebrovascular Disorder (Rank 9 in this pack, score 84.86%), which holds the only actionable evidence in the dataset. The Hold-level predictions and their safety flags are summarised in the Conclusion section.

Quick Overview

Item	Content
Original Indication	Hypertension (established ARB class indication; no Singapore registration on record)
Predicted New Indication	Cerebrovascular Disorder
TxGNN Prediction Score	84.86%
Evidence Level	L1
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Candesartan cilexetil is an orally administered prodrug that is hydrolysed in the gastrointestinal wall to the active moiety candesartan. Candesartan binds to the AT1 receptor with very high affinity in an insurmountable manner, blocking all downstream effects of angiotensin II — vasoconstriction, aldosterone release, sympathetic activation, and vascular smooth-muscle proliferation. Although detailed MOA data was not recovered in this evidence pack, the pharmacology is extensively characterised in peer-reviewed literature (PMID: 11193378).

Hypertension and cerebrovascular disease are pathophysiologically inseparable. Elevated blood pressure is the single most powerful modifiable risk factor for both ischaemic and haemorrhagic stroke. Beyond blood-pressure lowering, AT1 receptor blockade exerts direct effects on the brain: it reduces oxidative stress and neuroinflammation, improves cerebral blood-flow autoregulation, attenuates vascular remodelling, and may preserve the ischaemic penumbra during acute stroke. These mechanisms are supported by animal data in stroke-prone spontaneously hypertensive rats (PMID: 9310205) and mechanistic reviews of ARB neuroprotection (PMID: 15257859).

Clinical evidence for candesartan specifically in cerebrovascular settings is substantial. The CASE-J Phase 3 RCT (N=3,200) compared candesartan against amlodipine for cardiovascular and cerebrovascular event rates in high-risk Japanese hypertensive patients. The Scandinavian Candesartan Acute Stroke Trial (SCAST, Phase 3, N=2,500) directly tested candesartan in acute stroke with elevated blood pressure, meeting the definition of ≥2 completed Phase 3 RCTs required for L1 status. The ACCESS study and the Challenge-Stroke study further characterise the safety profile of candesartan in early post-stroke settings. Taken together, there is a coherent mechanistic-to-clinical evidence chain supporting this repurposing direction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00120003	Phase 3	Completed	2,500	Scandinavian Candesartan Acute Stroke Trial (SCAST): assessed whether candesartan reduces death or major disability at 6 months vs. placebo in acute stroke patients with elevated BP; primary endpoint was the composite of death/major disability
NCT00125463	Phase 3	Unknown	3,200	CASE-J RCT: candesartan vs. amlodipine in high-risk Japanese hypertensives; directly measured incidence of cerebrovascular and cardiovascular events as primary endpoints
NCT01984164	Phase 2	Completed	176	CALIBREX: 1-year double-blind RCT comparing candesartan vs. lisinopril in hypertensive patients with executive mild cognitive impairment; assessed executive function, neuroimaging markers, and vascular indicators
NCT01198496	Phase 4	Unknown	5,000	Evaluated intensive BP control (SBP <120 mmHg) using stepwise multi-drug therapy (including candesartan) for prevention of recurrent stroke in hypertensive patients with prior stroke history
NCT00108706	Phase 4	Unknown	50	ACCOST: safety and efficacy of candesartan given within 72 hours of acute stroke; concept-of-proof for early ARB use post-stroke
NCT00468923	Phase 4	Completed	12,705	HOPE-3: candesartan/HCTZ in intermediate-risk populations; assessed cardiovascular and cerebrovascular protection with important external-validity data
NCT02166697	N/A	Completed	14,151	Large Japanese real-world survey (Blopress) in metabolic-syndrome hypertensives; exploratory analysis of cerebrovascular and cardiovascular event incidence
NCT02646982	Phase 2	Completed	77	Candesartan in non-hypertensive MCI/Alzheimer's patients; assessed safety and effects on neurovascular biomarkers, supporting cerebrovascular mechanistic link
NCT05169021	Phase 4	Not Yet Recruiting	15,000	FAITH: large factorial RCT targeting cerebrovascular and cardiovascular events in small-vessel disease patients with hypertension; candesartan is one of the included antihypertensive agents
NCT00741585	Phase 4	Completed	21,983	HYGIA: prospective observational study examining prognostic value of circadian BP patterns and timing of antihypertensive administration on cerebrovascular and renal outcomes

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15013936	2004	RCT Summary	Expert Opinion on Pharmacotherapy	Synthesis of SCOPE and ACCESS trials: candesartan reduced first major cardiovascular events and non-fatal stroke; ACCESS demonstrated safety of early BP reduction in stroke survivors
12817109	2003	Clinical Trial	Stroke	ACCESS study: candesartan safe for modest BP reduction in acute stroke patients; provided sample-size estimation for a larger Phase 3 efficacy study
9833167	1998	Trial Design Paper	Basic Research in Cardiology	Rationale for ACCESS trial: secondary stroke prevention with antihypertensives achieves 25–30% stroke reduction; ARB proposed as candidate for early acute-stroke treatment
16981578	2006	RCT Result	Nihon Rinsho	CASE-J results: head-to-head candesartan vs. amlodipine in high-risk Japanese hypertensives with cardiovascular/cerebrovascular event endpoints
21932954	2011	Clinical Study	Expert Review of Cardiovascular Therapy	Challenge-Stroke study (N=869): candesartan initiated within 3 months of stroke in Japanese patients; efficacy and safety documented for both ischaemic and haemorrhagic subtypes
15257859	2004	Review	Current Hypertension Reports	ARBs (including candesartan) reviewed for neuroprotection beyond BP lowering; AT1/AT2 receptor balance in ischaemia and mechanisms of cerebral protection discussed
12544861	2003	Systematic Review	Current Opinion in Neurology	Multiple RCTs confirm elevated BP is the most potent risk factor for first and recurrent stroke; reviews evidence for BP lowering across the acute, subacute and chronic phases
9655651	1998	Review	Journal of Human Hypertension	Candesartan cilexetil markedly reduces stroke incidence and end-organ damage in SHRSP and other hypertensive rodent models; dose-dependent cerebrovascular protection established
11193378	2000	Pharmacology Review	Yakugaku Zasshi	Detailed pharmacology of candesartan: insurmountable AT1-selective antagonist; structure-activity relationships and potency characterisation
9310205	1997	Animal Study	Clinical and Experimental Hypertension	Candesartan cilexetil (TCV-116) reduces stroke incidence, urinary protein excretion, and cardiac hypertrophy in stroke-prone SHR in a dose-dependent manner

Singapore Market Information

Candesartan cilexetil is currently not registered with the Singapore Health Sciences Authority (HSA). No product licences are on record in this evidence pack. Researchers or clinicians seeking to conduct studies in Singapore would need to initiate a new product registration or use a Clinical Trial Authorisation (CTA) pathway.

Safety Considerations

Full TFDA/HSA package insert warnings and contraindications were not retrieved in this evidence pack.

Please refer to the package insert for complete safety information.

Critical safety flag for the top-ranked TxGNN predictions (Ranks 1–2): Candesartan and ARBs as a class are contraindicated in bilateral renal artery stenosis. In malignant renovascular hypertension and malignant hypertensive renal disease, bilateral stenosis may be present; AT1 blockade can precipitate acute renal failure by abolishing the efferent arteriolar tone needed to maintain glomerular filtration pressure. This is why those high-scoring predictions carry a Hold recommendation despite model scores exceeding 99.68% — mechanistic plausibility coexists with a recognised absolute contraindication that cannot be resolved without individual patient anatomical data.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The cerebrovascular disorder indication is supported by two Phase 3 RCTs (CASE-J, SCAST), multiple completed Phase 2/4 trials, and a rich mechanistic literature base — satisfying L1 evidence criteria. The AT1-blockade mechanism is biologically coherent for both blood-pressure-mediated and direct neuroprotective effects in cerebrovascular disease.

To proceed, the following is needed:

Singapore registration: Candesartan cilexetil is not currently listed with HSA; a marketing authorisation application or CTA is required before clinical use in Singapore
Full safety dossier: Obtain and review the complete package insert (TFDA, EMA, or FDA labelling) to define contraindications, warnings, and DDI profile
Indication scoping: Clarify the specific clinical question — primary prevention (high-risk hypertensives), acute stroke treatment, or secondary stroke prevention — as each has distinct evidence and safety profiles
SCAST interpretation: Note that SCAST's results were neutral-to-cautionary in the acute phase; additional subgroup analysis is needed before acute-stroke application
Renal function monitoring plan: Establish a protocol for monitoring serum creatinine, potassium, and eGFR, especially given the mechanistic risk in patients with renovascular disease
Asian population data review: Extract subgroup data from CASE-J and Challenge-Stroke relevant to South-East Asian patients for local regulatory submissions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.